MONTGOMERY, Texas--(BUSINESS WIRE)--AngioSoma, Inc. (OTCQB:SOAN) released an updated shareholder presentation this week summarizing the company’s activity over the last two months. Next week an audio discussion in a “fireside chat” format between Chairman Emeritus David P. Summers Ph.D. and CEO Alexanderia Blankenship will be released that will provide further details on a slide by slide basis. The presentation is available on our newly revised website’s home page (http://angiosoma.info), directly at http://angiosoma.info/shareholder-presentation-november-2016, and on the OTC Markets’ website at http://www.otcmarkets.com/stock/SOAN/video-and-presentations.
Please note the Company’s website properties have increased to accommodate greater information for shareholders and prospective investors alike. Our web properties include:
ABOUT ANGIOSOMA, INC.
AngioSoma, Inc. (OTCQB:SOAN, http://angiosoma.info) is a clinical stage biotechnology company focused on improving the effectiveness of current standard-of-care treatments related to pharmaceutical or endovascular interventions. Our “end to end” solution will provide interventional radiologists, cardiologists, and internal medicine physicians with both pharmaceutical and/or endovascular interventional options prior to infarction or critical limb ischemic events, stabilizing or reversing the atherosclerotic disease.
Our Soma Nutraceutical Inc. subsidiary aims to provide dietary anti-inflammatory, blood thinning, and anti-clotting natural products, as either stand alone or adjuncts to pharmaceutical care.
For pharmaceutical stabilization, our Liprostin™ product for treatment of peripheral artery disease (“PAD”) completed preliminary U.S. Food and Drug Administration (“FDA”) required Phase I and Phase II clinical trials successfully and is entering Phase III prior to approval. Our AngioSoma Research, Inc. subsidiary also owns the OmniCath I & II plaque debulking and vessel remodeling atherectomy catheter which will further support the stabilization of patients experiencing infarction or critical limb ischemic symptoms.
For long-term preventative measures, our Transdermal PGE-1 Patch will provide ongoing treatment for chronic cardiovascular disease by delivery of PGE-1 or Liprostin™ through the skin.
In all, we have a robust product pipeline from 20+ years of research and development, with existing patents, provisional patents, formulations, and trademarks from previously successful products.
NOTICE REGARDING FORWARD LOOKING STATEMENTS
This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, and other factors that may cause the actual results, performance, or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.